Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M

Xenon Pharmaceuticals Inc.

Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.
Company may offer and sell up to $250 million of common shares at-the-market on Nasdaq.
Sales agents Jefferies and Stifel will receive up to 3.0% commission on gross proceeds.
No minimum obligation to sell; program may be terminated by either party upon written notice.
Shares sold under existing shelf registration statement (File No. 333-260010) and prospectus supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.